JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
News
JPM26: BioNTech gears up for multiproduct oncology status by 2030
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Marea reports positive Phase I results for MAR002 trial in acromegaly
AbCellera begins Phase II ABCL635 trial for menopause-related VMS
JPM26: HIV pipeline dosing optionality gives Gilead advantage
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
